City Therapeutics CEO acquires 77,979 stock options

The option award has a $0.92 exercise price per share and expires December 10, 2034.

Rhea-AI Filing Summary

City Therapeutics, Inc. President & CEO Andrew C. Orth reported an acquisition of 77,979 stock options, originally granted December 11, 2024. The options vested in full when the company's initial public offering closed on October 19, 2026. They cover 77,979 common shares, have a $0.92 exercise price per share, and expire December 10, 2034.

Insider Trade Summary

Grant/Award: 77,979 shares

Grant/Award 1 txn

Insider ORTH ANDREW C.

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	77,979	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 77,979 contracts (Direct)

Footnotes (1)

1. F1. This stock option was originally granted to the Reporting Person on December 11, 2024. The shares vested in full upon closing of the Issuer's initial public offering on October 19, 2026.

Key Figures

Stock options acquired: 77,979 stock options Underlying common shares: 77,979 shares Exercise price: $0.92 per share +2 more

5 metrics

Stock options acquired 77,979 stock options Originally granted December 11, 2024

Underlying common shares 77,979 shares Shares covered by the options

Exercise price $0.92 per share Stock option exercise price

Options following transaction 77,979 stock options Reported resulting position

Expiration date December 10, 2034 Stock options

Key Terms

stock option, vested in full, initial public offering

3 terms

stock option financial

"stock option was originally granted"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vested in full financial

"shares vested in full upon closing"

initial public offering financial

"closing of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did CTY President & CEO Andrew C. Orth report?

Andrew C. Orth reported 77,979 stock options, originally granted December 11, 2024. They vested in full when City Therapeutics' initial public offering closed on October 19, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/19/2026 - 05:34 PM EDT Accepted by SEC EDGAR 10/19/2026 - 05:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ORTH ANDREW C.

(Last) (First) (Middle)

399 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CITY THERAPEUTICS, INC. [ CTY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.92	10/19/2026		A		77,979		(1)	12/10/2034	Common Stock	77,979	$0	77,979	D

Explanation of Responses:

1. This stock option was originally granted to the Reporting Person on December 11, 2024. The shares vested in full upon closing of the Issuer's initial public offering on October 19, 2026.

	/s/ Mary Beth DeLena, as Attorney-in-Fact	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)